Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.
Colorado clinic looking to help patients with ketamine-assisted psychotherapy
The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a ...
PC World14 天
Amazon Prime Video has ads now. Here’s how to stop them
Nope, there’s nothing wrong with your TV—that was an ad you just saw on Amazon Prime Video. Like many of the big streaming services, Amazon Prime Video has rolled out an ad-supported tier ...
Pharm Exec14 天
Spravato’s Transformative Impact: Offering Hope and Rapid Relief for Patients with Depression
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...
pharmaphorum15 天
NICE rejects J&J’s Spravato for treatment-resistant depression
The UK healthcare cost-effectiveness agency has said it will not recommend funding for Johnson & Johnson’s antidepressant nasal spray Spravato on the NHS, because of cost and clinical concerns.
verywellhealth16 天
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.
AOL17 天
FDA-approved nasal spray for severe depression can lead to remission
Now, the FDA has also approved Spravato for treating adults with MDD who have not responded to at least two oral antidepressants. According to J&J, Spravato is an N-methyl-D-aspartate (NMDA ...
Architectural Digest20 天
Watch: The AD PRO LIVE Road to AD100
new shops and products, travel destinations, art and cultural events, celebrity style, and high-end real estate as well as access to print features and images from the AD archives.
来自MSN20 天
FDA-Approved Nasal Spray For Depression Is First Of Its Kind
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...
Indiatimes21 天
FDA approves J&J’s nasal spray for severe depression as stand-alone treatment
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant depression. This marks a significant advancement in depression treatment ...
Too Old to Operate21 天
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
WEDNESDAY, Jan. 22, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...